Fit-for-purpose methodologies are critical to researchers seeking accurate results. Inaccurate results from
choosing the wrong cell counting method can lead to consequences such as lower quality of products, rejected
publications, repeated experiments, and lost time.
U.S. Congress as well as the National Institute of Standards and Technology (NIST), and other stakeholders, have
identified that cell counting and viability measurement assurance are important standards for improving the
quality of cell therapy products.